Results 21 to 30 of about 14,668 (165)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma

open access: yesFrontiers in Oncology, 2022
BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion
Francesca Bonello   +18 more
doaj   +1 more source

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

open access: yesHemaSphere, 2023
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16), but
Christie P.M. Verkleij   +26 more
doaj   +1 more source

Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers

open access: yesFrontiers in Oncology, 2023
Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration ...
Gordon Cook   +8 more
doaj   +1 more source

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

open access: yesFrontiers in Immunology, 2022
RationaleRecent studies have demonstrated the feasibility of CD38-specific antibody constructs for in vivo imaging of multiple myeloma. However, detecting multiple myeloma in daratumumab-pretreated patients remains difficult due to overlapping binding ...
Luca Julius Pape   +14 more
doaj   +1 more source

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

open access: yesHaematologica, 2020
Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of ...
Jesus San-Miguel   +16 more
doaj   +1 more source

Daratumumab efficacy in extramedullary orbital myeloma [PDF]

open access: yes, 2020
Daratumumab is very efficacious in multiple myeloma. Few reports are present about efficacy in extramedullary myeloma. We report here daratumumab efficacy in extramedullary ocular myeloma in a young 46‐year‐old man diagnosed 3 years earlier and relapse ...
Bocchia, Monica   +5 more
core   +1 more source

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA [PDF]

open access: yes, 2017
The use of proteasome inhibitors and immunomodulatory drugs in the clinical practice has contributed to the significant improvement in survival for patients with multiple myeloma over the past decades.
V. V. Ryzhko, M. L. Kanaeva
core   +2 more sources

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

open access: yesJournal of International Medical Research, 2021
Objective To systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM). Methods A systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library,
Yin Wang, Yanqing Li, Ye Chai
doaj   +1 more source

Daratumumab in AL amyloidosis [PDF]

open access: yes, 2022
Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct fibril typing,
Sanchorawala, V, Wechalekar, AD
core   +1 more source

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

open access: yesHaematologica, 2020
CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple
Anna Vidal-Crespo   +17 more
doaj   +1 more source

Home - About - Disclaimer - Privacy